Vincerx Pharma, Inc.
VINC
$0.809
-$0.0102-1.25%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.89M | 3.61M | 2.92M | 1.82M | 3.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.79M | 7.37M | 7.48M | 5.53M | 9.61M |
| Operating Income | -7.79M | -7.37M | -7.48M | -5.53M | -9.61M |
| Income Before Tax | -7.84M | -1.81M | -12.43M | -4.95M | -9.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.84M | -1.81M | -12.43M | -4.95M | -9.01M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.84M | -1.81M | -12.43M | -4.95M | -9.01M |
| EBIT | -7.79M | -7.37M | -7.48M | -5.53M | -9.61M |
| EBITDA | -7.78M | -7.35M | -7.47M | -5.52M | -9.60M |
| EPS Basic | -5.00 | -1.21 | -11.62 | -4.63 | -8.44 |
| Normalized Basic EPS | -3.12 | -0.76 | -7.26 | -2.90 | -5.27 |
| EPS Diluted | -5.00 | -1.21 | -11.62 | -4.63 | -8.44 |
| Normalized Diluted EPS | -3.12 | -0.76 | -7.26 | -2.90 | -5.27 |
| Average Basic Shares Outstanding | 1.57M | 1.49M | 1.07M | 1.07M | 1.07M |
| Average Diluted Shares Outstanding | 1.57M | 1.49M | 1.07M | 1.07M | 1.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
